Maze Therapeutics (MAZE) Equity Ratio (2024 - 2026)

Maze Therapeutics has disclosed Equity Ratio across 3 years of filings, most recently posting 0.81 for Q1 2026.

• Equity Ratio for Q1 2026 came in at 0.81, down 7.22% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.81 (down 7.22% YoY), and the FY2025 annual result was 0.89, up 169.09% from the prior year.
• Equity Ratio came in at 0.81 for Q1 2026 at Maze Therapeutics, down from 0.89 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.9 in Q3 2025 to a low of 1.29 in Q4 2024.
• The 3-year median for Equity Ratio is 0.87 (2025), against an average of 0.51.
• Across the five-year window, Equity Ratio soared 169.09% in 2025 and declined 7.22% in 2026, its largest moves.
• Maze Therapeutics' Equity Ratio stood at 1.29 in 2024, then surged by 169.09% to 0.89 in 2025, then slipped by 8.92% to 0.81 in 2026.
• The last three Equity Ratio figures came in at 0.81 (Q1 2026), 0.89 (Q4 2025), and 0.9 (Q3 2025), per Business Quant data.